A LITERARY REVIEW OFTHE CONTENTS OF THULASI ENNAI (PEDIATRIC SIDDHA FORMULATION) IN THE MANAGEMENT OF PEDIATRIC BRONCHIAL ASTHMA

Objectives: The purpose of this review article is focused on the photochemical constituents and therapeutic potential of Thulasi Ennai to combat pediatric bronchial asthma. Methods: The electronic databases such as Google Scholar, Medline/PubMed, Web of Science, Science Direct, Scopus and Directory of Open Access Journals (DOAJ), and reference lists have been looked to identify publications pertinent to the individual herbs of Thulasi Ennai. Results: The pharmacological effects of the herbs found in Thulasi Ennai possess anti-asthmatic, anti-inflammatory, antibacterial, antiviral, and other pharmacological effects relevant to the management of bronchial asthma. Conclusion: The present review concluded the safety of the Thulasi Ennai in preclinical studies. Further, clinical studies of Thulasi Ennai would need to be performed in humans to assess the efficacy of Thulasi Ennai

5-Fluoro-6′H,7′H,8′H-spiro­[indoline-3,7′-pyrano[3,2-c:5,6-c′]di-1-benzopyran]-2,6′,8′-trione

In the title compound, C26H12FNO6, the central pyran ring and both benzopyran systems are nonplanar, having total puckering amplitudes of 0.139 (2), 0.050 (1) and 0.112 (2) Å, respectively. The central pyran ring adopts a boat conformation. The crystal structure is stabilized by C—H⋯O, N—H⋯O, N—H⋯F and C—H⋯π inter­actions

Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation

Abstract Background Currently, no vaccines or modern drugs are available for dengue and chikungunya and only symptomatic relief is provided to the patients. Siddha medicine, a traditional form of indigenous medical system uses specific polyherbal formulations for the treatment of such infections with considerable success. One such polyherbal formulation for the treatment of chikungunya and dengue is Nilavembu kudineer (NVK). The mechanistic details of this drug as an antiviral for chikungunya virus (CHIKV) and dengue virus (DENV) is poorly understood. Objectives The current study was undertaken to study the efficacy of NVK as an antiviral formulation against CHIKV and DENV. Materials and methods Cytotoxicity assays (MTT) were performed to determine the role of NVK as an antiviral during chikungunya and dengue infections in the following conditions-i). post infection, ii). during active infections and iii) protective, not allowing virus infection. Results It was observed that NVK provides protection against CHIKV and DENV-2 during active infection as well can help to prevent virus infection in the cells and it mainly depends on the cellular availability of drugs for maximum protection against both the infections. Conclusion Our study establishes that extraction protocols are important to ensure maximum efficacy of NVK along with the time of addition of the drug during CHIKV and DENV infections in the cells. This study provides insights to the possible mode of action of NVK in in vitro condition during CHIKV and DENV infection

Screening of Influenza a (H1N1) Neuraminidase Inhibitor for Kabasura Kudineer, Nilavembu Kudineer and the Novel Formulation JACOM

Due to erratic climate change, vector-borne diseases started flaring up from the second half of the last decade. Siddha medicine has been used as a public health tool to effectively manage chikungunya and dengue in the epidemics that happened in 2008 and 2016. Tamil Nadu government has made enormous efforts to control vector-borne diseases. Due to which morbidity and mortality due to vector borne diseases came down compared with other states. Two official Siddha formulations, namely Kabasura Kudineer Chooranam and Nilavembu Kudineer Chooranam and novel herbal formulation – JACOM, are used to combat vector-borne diseases. These decoctions lack an evidence base as a formulation. Screening has been done to check the efficacy of the formulation in inhibiting neuraminidase. Neuraminidase inhibition assay was performed to determine the activity of Siddha formulations. The Kabasura Kudineer Chooranam, Nilavembu Kudineer Chooranam and JACOM showed excellent inhibitory activity. The Kabasura Kudineer and Nilavembu Kudineer and JACOM aqueous extract showed maximum neuraminidase inhibition of 80.35%, 91.78% and 87.97%, respectively.</p

Urolithiasis (Kalladaippu) - An Evidence Based Case Study

“KALLADAIPPU†(Urolithiasis) “KALPIRAMIYAMâ€(Urolithiasis) are the synonyms in Siddha and the term equated to renal calculi in allopathic system of medicines. An increasing affluence and adaptation of Western diet habits in many developing countries seem likely to contribute to the changes for the development of renal calculi. Siddha medicine describes certain formulations as Lithotriptic and diuretic which is used in the treatment of renal calculi successfully. This case reported again is an example that proves the efficacy of Siddha medicines for expulsion of renal stones. The synergistic action enhanced resulting in disintegration and elimination of urinary stones from urinary tract

In Silico Docking Analysis of Poly Herbal Formulation Aadathodai Kudineer used in Siddha medicine in inhibiting Main Protease and ACE2 Receptor Spike protein SARS-CoV-2

Corona virus disease (COVID-19) is an infectious pandemic disease caused by the newly discovered novel corona virus. World Health Organization has declared the global health emergency due to COVID19 outbreak. Currently, there is no specific treatment or vaccine for fighting against this infectious disease. Aadathodai Kudineer is a drug indicated for Iya Erumal, Kozhai Kattu, Kabasuram. Upon the mortality and severity of the disease COVID19, we tried to identify the possible inhibition of phytocomponents of Aadathodai Kudineer in inhibiting Main Protease and ACE2 Receptor Spike protein SARS-CoV-2 through molecular docking studies. Methodology: In Silico molecular docking analysis was performed for phytocomponents present in the Aadathodai Kudineer formulation for targets main protease and ACE2 Receptor Spike protein, PDB ID: 6LU7 and PDB ID: 2AJF using Autodock tool. ADME properties was also predicted for all the above compounds. Results: Among the 9 active Phytocompounds present in the Aadathodai Kudineer formulation, Lupeol showed high binding affinity with COVID19 main protease and ACE2 receptor which shows the promising contrivance of protease inhibition. The ADME suggested that the formulation is free from toxic. Conclusion: The phytocomponents showed possible affinity towards these targets and has the lead molecules that inhibits COVID19 main protease and ACE2 receptor.&nbsp

Aqueous extract of large cardamom inhibits vascular damage, oxidative stress, and metabolic changes in fructose-fed hypertensive rats

Purpose Since metabolic abnormalities such as elevated glucose level and imbalanced lipid profiles increase the risk for hypertension and cause endothelial dysfunction, we evaluated the effect of aqueous extract of large cardamom (AELC) on fructose-induced metabolic hypertension and oxidative stress Methods The male Sprague-Dawley rats were divided into 6 groups with 5 rats in each group, and each group was fed with 10% fructose in drinking water for 8 weeks. Starting from week 5, animals were treated with 50, 100, and 200 mg/kg/day AELC or Losartan (10 mg/kg/day). Systolic, diastolic, and mean arterial blood pressure was measured once in every seven days using the tail-cuff method. Vascular function, plasma nitric oxide (NO), glucose, lipid profiles, serum biochemical, and anti-oxidant parameters were also evaluated. Results Rats fed with fructose showed higher blood pressure, serum cholesterol, and triglyceride levels, but decreased in the AELC or Losartan treatment group. Treatments with AELC prevented exaggerated plasma glucose and oxidative stress and restored the nitric oxide level in fructose-fed rats. Besides, it also reduced vascular proliferation and improved the relaxation response of acetylcholine in the aorta pre-contracted with phenylephrine. Conclusion In summary, the obtained results suggest that AELC can prevent and reverse the high blood pressure induced by fructose, probably by restoring nitric oxide level and by improving altered metabolic parameters